个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

A promising predictive biomarker combined EBV NDA with PNI for nasopharyngeal carcinoma in nonendemic area of China

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
He Qiao[1,2] ; Huang Yecai[3] ; Yuan Linjia[4] ; Wang Zuo[1,2] ; Wang Qiuju[2] ; Liu Daduan[1,5] ; Li Luona[2] ; Li Xianbing[2] ; Cao Zhi[4] ; Wang Dongsheng[1,2] ; Yang Mu[1,5] ;
机构： [1]School of Medicine, University of Electronic Science and Technology of China, Chengdu, China [2]Department of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, No. 55, South Renmin Road, Chengdu 610041, China [3]Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, No. 55, South Renmin Road, Chengdu 610041, China [4]Department of Radiation Oncology, Jinjiang Da Guan Hospital of Chengdu, Chengdu, China [5]Centre for Translational Research, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
出处：
DOI： 10.1038/s41598-023-38396-z
ISSN：

摘要：
In endemic areas, EBV DNA is used to guide diagnosis, detect recurrence and distant metastasis of NPC. Until now, the importance of EBV DNA in the prediction of NPC has received little attention in non-endemic regions. To explore the prognostic value of EBV DNA alone or in combination with PNI in NPC patients from a non-endemic area of China. In this retrospective study, 493 NPC patients were enrolled. Clinical pathologic data, pre-treatment plasma EBV DNA, and laboratory tests were all performed. A standard anticancer treatment was prescribed, and follow up data were collected. EBV DNA was found to be positively related to clinical stage (r = 0.357, P < 0.001), T stage (r = 0.193, P < 0.001), N stage (r = 0.281, P < 0.001), and M stage (r = 0.215, P < 0.001). The difference in EBV DNA loads between clinical stage, T, N and M stage was statistically significant (P < 0.001). In this study, the best cutoff value for EBV-DNA to distinguish the prognosis of NPC was 262.7 copies/ml. The 5-year OS of patients in the EBV-DNA ≤ 262.7 copies/ml group and EBV-DNA > 262.7 copies/ml group was 88% and 65.3%, respectively (P < 0.001). EBV-DNA and PNI were found to be independent prognostic factors for OS in multivariate analysis (P < 0.05). EBV-DNA was independent prognostic factors for PFS. In predicting NPC patients OS, the novel combination marker of EBV DNA and PNI outperformed TNM staging (AUC: 0.709 vs. 0.675). In addition, the difference between EBV + PNI and EBV + TNM was not statistically significant for OS or PFS (P > 0.05). This novel combination biomarker was a promising biomarker for predicting NPC survival and may one day guide treatment option.© 2023. The Author(s).

基金：
This study was supported by Sichuan Provincial Cadre Health Research Project (Chuan Gan Yan 2021-804); Support Project of Chengdu Science and Technology (No.2021-YF05-01792-SN, 2021-YF05-02064-SN), and Sichuan Science and Technology Program (No.2022YFS0006). Natural Science Foundation of Sichuan Province (23NSFSC4904).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 2 区 综合性期刊
小类 | 2 区 综合性期刊
最新[2023]版：
大类 | 2 区 综合性期刊
小类 | 2 区 综合性期刊
JCR分区：
出版当年[2023]版：
Q1 MULTIDISCIPLINARY SCIENCES
最新[2023]版：
Q1 MULTIDISCIPLINARY SCIENCES

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]School of Medicine, University of Electronic Science and Technology of China, Chengdu, China [2]Department of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, No. 55, South Renmin Road, Chengdu 610041, China
通讯作者：
通讯机构： [1]School of Medicine, University of Electronic Science and Technology of China, Chengdu, China [2]Department of Clinical Laboratory, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, No. 55, South Renmin Road, Chengdu 610041, China [5]Centre for Translational Research, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
推荐引用方式(GB/T 7714)：
He Qiao,Huang Yecai,Yuan Linjia,et al.A promising predictive biomarker combined EBV NDA with PNI for nasopharyngeal carcinoma in nonendemic area of China[J].SCIENTIFIC REPORTS.2023,13(1):doi:10.1038/s41598-023-38396-z.
APA：
He Qiao,Huang Yecai,Yuan Linjia,Wang Zuo,Wang Qiuju...&Yang Mu.(2023).A promising predictive biomarker combined EBV NDA with PNI for nasopharyngeal carcinoma in nonendemic area of China.SCIENTIFIC REPORTS,13,(1)
MLA：
He Qiao,et al."A promising predictive biomarker combined EBV NDA with PNI for nasopharyngeal carcinoma in nonendemic area of China".SCIENTIFIC REPORTS 13..1(2023)

资源点击量：43389 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号